Symbols

ATAI

AtaiBeckley·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

Significant Net Income Decline

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About ATAI

Ataibeckley Inc.

A clinical-stage biopharmaceutical company that developing treatment for mental health disorders

Industry

Pharmaceutical

Established Date

09/10/2020

Listing Date

06/18/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ataibeckley.com

Security Type

Common stock

Office address

250 West 34th Street, New York, NY 10119

Business

Introduction

AtaiBeckley Inc., was incorporated under the laws of the Netherlands on September 10, 2020. On January 11, 2021, it was renamed ATAI Life Sciences B.V. On November 5, 2025, it was renamed Atai Beckley N.V. On January 2, 2026, the company name was changed to AtaiBeckley Inc., and it was transformed into a company incorporated under the laws of the State of Delaware. The company is a clinical-stage biotechnology company focused on the development of new, psychedelic-based neuroplastic drugs for difficult-to-treat mental health disorders. Its R&D pipeline includes research projects for treatment-resistant depression and social anxiety disorder, as well as a drug discovery program for novel non-hallucinogenic compounds.

Company Financials

EPS

ATAI has released its 2025 Q4 earnings. EPS was reported at -1.73, versus the expected -0.12, missing expectations. The chart below visualizes how ATAI has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

ATAI has released its 2025 Q4 earnings report, with revenue of 1.07M, reflecting a YoY change of 21420.00%, and net profit of -544.84M, showing a YoY change of -1297.34%. The Sankey diagram below clearly presents ATAI's revenue sources and cost distribution.